PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy

NCT00335868 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: danusertib
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]